{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:09:33Z","timestamp":1792789773417,"version":"4.5.0"},"reference-count":180,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21bm0804005"],"award-info":[{"award-number":["JP21bm0804005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21im0210115"],"award-info":[{"award-number":["JP21im0210115"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0109293"],"award-info":[{"award-number":["JP19ek0109293"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21bm0104001"],"award-info":[{"award-number":["JP21bm0104001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["19H02924"],"award-info":[{"award-number":["19H02924"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009438","name":"National Center of Neurology and Psychiatry","doi-asserted-by":"publisher","award":["28-6"],"award-info":[{"award-number":["28-6"]}],"id":[{"id":"10.13039\/501100009438","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.jconrel.2022.01.013","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T11:09:06Z","timestamp":1641812946000},"page":"345-361","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":259,"special_numbering":"C","title":["Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges"],"prefix":"10.1016","volume":"342","author":[{"given":"Eman A.","family":"Taha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akitsu","family":"Hotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6096","key":"10.1016\/j.jconrel.2022.01.013_bb0005","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.1225829","article-title":"A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity","volume":"337","author":"Jinek","year":"2012","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.jconrel.2022.01.013_bb0010","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.apsb.2021.05.020","article-title":"In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges","volume":"11","author":"Behr","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/biom10060839","article-title":"Recent advance in CRISPR\/Cas9 delivery strategies","volume":"10","author":"Yip","year":"2020","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.jconrel.2022.01.013_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3107","article-title":"Delivery of CRISPR\/Cas9 for therapeutic genome editing","volume":"21","author":"Xu","year":"2019","journal-title":"J. Gene Med."},{"issue":"10","key":"10.1016\/j.jconrel.2022.01.013_bb0025","doi-asserted-by":"crossref","first-page":"24751","DOI":"10.3390\/ijms161024751","article-title":"Minimizing off-target mutagenesis risks caused by programmable nucleases","volume":"16","author":"Ishida","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jbiotec.2015.04.024","article-title":"Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection","volume":"208","author":"Liang","year":"2015","journal-title":"J. Biotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-017-0066","article-title":"Engineering CRISPR-Cpf1 crRNAs and mRNAs to maximize genome editing efficiency","volume":"1","author":"Li","year":"2017","journal-title":"Nat. Biomed. Eng."},{"issue":"4","key":"10.1016\/j.jconrel.2022.01.013_bb0040","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.stemcr.2021.02.013","article-title":"Efficient ssODN-mediated targeting by avoiding cellular inhibitory RNAs through Precomplexed CRISPR-Cas9\/sgRNA ribonucleoprotein","volume":"16","author":"Kagita","year":"2021","journal-title":"Stem Cell Rep."},{"issue":"15","key":"10.1016\/j.jconrel.2022.01.013_bb0045","doi-asserted-by":"crossref","first-page":"8322","DOI":"10.1128\/JVI.78.15.8322-8332.2004","article-title":"Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation","volume":"78","author":"Ludwig","year":"2004","journal-title":"J. Virol."},{"issue":"24","key":"10.1016\/j.jconrel.2022.01.013_bb0050","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1002\/1873-3468.13691","article-title":"State-of-the-art human adenovirus vectorology for therapeutic approaches","volume":"593","author":"Gao","year":"2019","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0055","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1146\/annurev-virology-031413-085355","article-title":"AAV-mediated gene therapy for research and therapeutic purposes","volume":"1","author":"Samulski","year":"2014","journal-title":"Annu. Rev. Virol."},{"issue":"10","key":"10.1016\/j.jconrel.2022.01.013_bb0060","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.gt.3302233","article-title":"Gene therapy Progress and prospects: recombinant adeno-associated virus (rAAV) vectors","volume":"11","author":"Flotte","year":"2004","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2022.01.013_bb0065","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2174\/1566523054064968","article-title":"AAV hybrid serotypes: improved vectors for gene delivery","volume":"5","author":"Choi","year":"2005","journal-title":"Curr. Gene Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2022.01.013_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-associated virus serotypes: vector toolkit for human gene therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"13","key":"10.1016\/j.jconrel.2022.01.013_bb0075","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0080","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omtm.2019.12.004","article-title":"AAV-mediated CRISPR\/Cas9 gene editing in murine phenylketonuria","volume":"17","author":"Richards","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"7","key":"10.1016\/j.jconrel.2022.01.013_bb0085","doi-asserted-by":"crossref","first-page":"eaax5701","DOI":"10.1126\/sciadv.aax5701","article-title":"A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"issue":"3\u20134","key":"10.1016\/j.jconrel.2022.01.013_bb0090","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41434-019-0116-1","article-title":"The deletion of mutant SOD1 via CRISPR\/Cas9\/sgRNA prolongs survival in an amyotrophic lateral sclerosis mouse model","volume":"27","author":"Duan","year":"2020","journal-title":"Gene Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0095","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1161\/CIRCULATIONAHA.119.042476","article-title":"In vivo AAV-CRISPR\/Cas9-mediated gene editing ameliorates atherosclerosis in familial hypercholesterolemia","volume":"141","author":"Zhao","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0100","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.omtn.2018.12.008","article-title":"Viral vector-based delivery of CRISPR\/Cas9 and donor DNA for homology-directed repair in an in vitro model for canine hemophilia B","volume":"14","author":"Gao","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0105","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ymthe.2016.11.010","article-title":"CRISPR\/Cas9 editing of the mutant huntingtin allele in vitro and in vivo","volume":"25","author":"Monteys","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0110","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/s41467-019-14181-3","article-title":"Single AAV-mediated mutation replacement genome editing in limited number of photoreceptors restores vision in mice","volume":"11","author":"Nishiguchi","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0115","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/s41467-018-04175-y","article-title":"CRISPR-LbCpf1 prevents choroidal neovascularization in a mouse model of age-related macular degeneration","volume":"9","author":"Koo","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0120","doi-asserted-by":"crossref","first-page":"14716","DOI":"10.1038\/ncomms14716","article-title":"Nrl knockdown by AAV-delivered CRISPR\/Cas9 prevents retinal degeneration in mice","volume":"8","author":"Yu","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0125","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41467-017-00140-3","article-title":"Genome editing abrogates angiogenesis in vivo","volume":"8","author":"Huang","year":"2017","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymthe.2016.12.006","article-title":"CRISPR\/Cas9-mediated genome editing as a therapeutic approach for Leber congenital Amaurosis 10","volume":"25","author":"Ruan","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0135","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-018-0327-9","article-title":"Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10","volume":"25","author":"Maeder","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0140","doi-asserted-by":"crossref","first-page":"14454","DOI":"10.1038\/ncomms14454","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.jconrel.2022.01.013_bb0145","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ymthe.2020.05.024","article-title":"Correction of three prominent mutations in mouse and human models of Duchenne muscular dystrophy by single-cut genome editing","volume":"28","author":"Min","year":"2020","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2022.01.013_bb0150","doi-asserted-by":"crossref","first-page":"eaav4324","DOI":"10.1126\/sciadv.aav4324","article-title":"CRISPR-Cas9 corrects Duchenne muscular dystrophy exon 44 deletion mutations in mice and human cells","volume":"5","author":"Min","year":"2019","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.jconrel.2022.01.013_bb0155","doi-asserted-by":"crossref","first-page":"eaay6812","DOI":"10.1126\/sciadv.aay6812","article-title":"Enhanced CRISPR-Cas9 correction of Duchenne muscular dystrophy in mice by a self-complementary AAV delivery system","volume":"6","author":"Zhang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0160","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1038\/s41467-019-12335-x","article-title":"In vivo non-invasive monitoring of dystrophin correction in a new Duchenne muscular dystrophy reporter mouse","volume":"10","author":"Amoasii","year":"2019","journal-title":"Nat. Commun."},{"issue":"19","key":"10.1016\/j.jconrel.2022.01.013_bb0165","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0170","series-title":"Editas Early Data for CRISPR Therapy EDIT-101 Shows Efficacy \u2018Signals\u2019 in Two Patients","author":"Philippidis","year":"2021"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0175","doi-asserted-by":"crossref","unstructured":"First CRISPR therapy dosed, Nat. Biotechnol., vol. 38, no. 4, pp. 382\u2013382, Apr. 2020, doi: https:\/\/doi.org\/10.1038\/s41587-020-0493-4.","DOI":"10.1038\/s41587-020-0493-4"},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0180","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.ymthe.2020.03.018","article-title":"A highly efficacious PS gene editing system corrects metabolic and neurological complications of mucopolysaccharidosis type I","volume":"28","author":"Ou","year":"2020","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2019000007","article-title":"Gene therapy for hemophilia","volume":"2019","author":"Nathwani","year":"2019","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0190","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-14-0250","article-title":"Zinc finger nucleases targeting the human papillomavirus E7 oncogene induce E7 disruption and a transformed phenotype in HPV16\/18-positive cervical cancer cells","author":"Ding","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0195","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1172\/JCI78206","article-title":"TALEN-mediated targeting of HPV oncogenes ameliorates HPV-related cervical malignancy","volume":"125","author":"Hu","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0200","article-title":"Disruption of HPV16-E7 by CRISPR\/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical Cancer cells","volume":"Jul. 2014","author":"Hu","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0205","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/d41573-020-00096-y","article-title":"Gene-editing pipeline takes off","volume":"19","author":"Mullard","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0210","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/s41587-020-00781-8","article-title":"Targeting herpes simplex virus with CRISPR-Cas9 cures herpetic stromal keratitis in mice","volume":"39","author":"Yin","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0215","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2022.01.013_bb0220","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0225","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0230","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.ymthe.2020.04.017","article-title":"AAV-CRISPR gene editing is negated by pre-existing immunity to Cas9","volume":"28","author":"Li","year":"2020","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2022.01.013_bb0235","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N","article-title":"Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)","volume":"59","author":"Erles","year":"1999","journal-title":"J. Med. Virol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0240","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0245","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/gt.2012.20","article-title":"Directed evolution of novel adeno-associated viruses for therapeutic gene delivery","volume":"19","author":"Bartel","year":"2012","journal-title":"Gene Ther."},{"issue":"10","key":"10.1016\/j.jconrel.2022.01.013_bb0250","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.3390\/genes11101113","article-title":"Delivery approaches for therapeutic genome editing and challenges","volume":"11","author":"Ates","year":"2020","journal-title":"Genes"},{"issue":"11","key":"10.1016\/j.jconrel.2022.01.013_bb0255","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"3","key":"10.1016\/j.jconrel.2022.01.013_bb0260","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman Primates and piglets following High-dose intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0265","author":"Audentes press release"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0270","author":"Audentes press release"},{"issue":"3","key":"10.1016\/j.jconrel.2022.01.013_bb0275","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41591-019-0344-3","article-title":"Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy","volume":"25","author":"Nelson","year":"2019","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0280","doi-asserted-by":"crossref","first-page":"4439","DOI":"10.1038\/s41467-019-12449-2","article-title":"High levels of AAV vector integration into CRISPR-induced DNA breaks","volume":"10","author":"Hanlon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0285","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.omtm.2018.11.009","article-title":"A self-deleting AAV-CRISPR system for in vivo genome editing","volume":"12","author":"Li","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0290","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"13","key":"10.1016\/j.jconrel.2022.01.013_bb0295","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1093\/nar\/gkv601","article-title":"Development of an intein-mediated split\u2013Cas9 system for gene therapy","volume":"43","author":"Truong","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0300","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nbt.3149","article-title":"A Split Cas9 architecture for inducible genome editing and transcription modulation","volume":"33","author":"Zetche","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"7546","key":"10.1016\/j.jconrel.2022.01.013_bb0305","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature14299","article-title":"In vivo genome editing using Staphylococcus aureus Cas9","volume":"520","author":"Ran","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0310","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0315","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/s41467-018-08224-4","article-title":"Engineering of CRISPR-Cas12b for human genome editing","volume":"10","author":"Strecker","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0320","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: the first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.jconrel.2022.01.013_bb0325","doi-asserted-by":"crossref","first-page":"5978","DOI":"10.1128\/JVI.02650-06","article-title":"New adenovirus species found in a patient presenting with gastroenteritis","volume":"81","author":"Jones","year":"2007","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.jconrel.2022.01.013_bb0330","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1128\/JCM.02354-07","article-title":"Epidemic keratoconjunctivitis due to the novel hexon-chimeric-intermediate 22,37\/H8 human adenovirus","volume":"46","author":"Aoki","year":"2008","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0335","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jconrel.2019.02.009","article-title":"Long-term correction of hemophilia B using adenoviral delivery of CRISPR\/Cas9","volume":"298","author":"Stephens","year":"2019","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0340","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0345","first-page":"31","article-title":"HIV-1-derived lentiviral vectors","volume":"261","author":"Ailles","year":"2002","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0350","first-page":"529","article-title":"Non-primate lentiviral vectors","volume":"5","author":"Poeschla","year":"2003","journal-title":"Curr. Opin. Mol. Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0355","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1128\/JVI.77.5.2964-2971.2003","article-title":"A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector","volume":"77","author":"Kubo","year":"2003","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0360","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/hum.2005.16.741","article-title":"Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses","volume":"16","author":"Abordo-Adesida","year":"2005","journal-title":"Hum. Gene Ther."},{"issue":"5644","key":"10.1016\/j.jconrel.2022.01.013_bb0365","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1126\/science.1088547","article-title":"LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1","volume":"302","author":"Hacein-Bey-Abina","year":"2003","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.jconrel.2022.01.013_bb0370","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/s41591-018-0049-z","article-title":"CRISPR-Cas9 genome editing induces a p53-mediated DNA damage response","volume":"24","author":"Haapaniemi","year":"2018","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2022.01.013_bb0375","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nbt.2623","article-title":"High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells","volume":"31","author":"Fu","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0380","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.omtm.2017.04.002","article-title":"Integrase-deficient lentiviral vector as an all-in-one platform for highly efficient CRISPR\/Cas9-mediated gene editing","volume":"5","author":"Ortinski","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0385","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2021.02.022","article-title":"Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease","volume":"21","author":"Uchida","year":"2021","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0390","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S1525-0016(03)00134-5","article-title":"Characterization and detection of artificial replication-competent lentivirus of altered host range","volume":"8","author":"Segall","year":"2003","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0395","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0400","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.addr.2020.06.024","article-title":"Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications","volume":"156","author":"Chung","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.jconrel.2022.01.013_bb0405","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1080\/14760584.2018.1516552","article-title":"Virus-like particle vaccines: immunology and formulation for clinical translation","volume":"17","author":"Donaldson","year":"2018","journal-title":"Expert Rev. Vaccines"},{"issue":"7","key":"10.1016\/j.jconrel.2022.01.013_bb0410","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/gt.2016.27","article-title":"Lentivirus pre-packed with Cas9 protein for safer gene editing","volume":"23","author":"Choi","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0415","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.omtn.2018.05.010","article-title":"VSV-G-enveloped vesicles for traceless delivery of CRISPR-Cas9","volume":"12","author":"Montagna","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0420","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41467-018-07845-z","article-title":"Genome editing in primary cells and in vivo using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins","volume":"10","author":"Mangeot","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0425","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymthe.2018.10.002","article-title":"Gesicle-mediated delivery of CRISPR\/Cas9 ribonucleoprotein complex for inactivating the HIV provirus","volume":"27","author":"Campbell","year":"2019","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0430","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41467-020-14957-y","article-title":"Extracellular nanovesicles for packaging of CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping","volume":"11","author":"Gee","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0435","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1476-5381.2009.00057.x","article-title":"Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics","volume":"157","author":"Heitz","year":"2009","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.jconrel.2022.01.013_bb0440","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tips.2017.01.003","article-title":"Cell-penetrating peptides: from basic research to clinics","volume":"38","author":"Guidotti","year":"2017","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13060878","article-title":"Efficient Peptide-Mediated In Vitro Delivery of Cas9 RNP","volume":"13","author":"Gustafsson","year":"2021","journal-title":"Pharmaceutics"},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0450","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s12257-020-0068-8","article-title":"Non-viral gene disruption by CRISPR\/Cas9 delivery using cell-permeable and protein-stabilizing 30Kc19 protein","volume":"25","author":"Kim","year":"2020","journal-title":"Biotechnol. Bioprocess Eng."},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0455","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt.3806","article-title":"Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes","volume":"35","author":"Staahl","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0460","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41434-019-0119-y","article-title":"Integrating gene delivery and gene-editing technologies by adenoviral vector transfer of optimized CRISPR-Cas9 components","volume":"27","author":"Maggio","year":"2020","journal-title":"Gene Ther."},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0465","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/molecules24050927","article-title":"Recent advances in cell penetrating peptide-based anticancer therapies","volume":"24","author":"Habault","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0470","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/s41551-017-0137-2","article-title":"Nanoparticle delivery of Cas9 ribonucleoprotein and donor DNA in vivo induces homology-directed DNA repair","volume":"1","author":"Lee","year":"2017","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0475","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jconrel.2021.02.026","article-title":"Co-encapsulation of Cas9 mRNA and guide RNA in polyplex micelles enables genome editing in mouse brain","volume":"332","author":"Abbasi","year":"2021","journal-title":"J. Control. Release"},{"issue":"25","key":"10.1016\/j.jconrel.2022.01.013_bb0480","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"7830","key":"10.1016\/j.jconrel.2022.01.013_bb0485","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.jconrel.2022.01.013_bb0490","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1021\/acs.molpharmaceut.1c00447","article-title":"Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines","volume":"18","author":"Chatzikleanthous","year":"2021","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.jconrel.2022.01.013_bb0495","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","article-title":"Lipid nanoparticle Systems for Enabling Gene Therapies","volume":"25","author":"Cullis","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"10","key":"10.1016\/j.jconrel.2022.01.013_bb0500","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020401118","article-title":"Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3","volume":"118","author":"Qiu","year":"2021","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.jconrel.2022.01.013_bb0505","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1016\/j.celrep.2018.02.014","article-title":"A single administration of CRISPR\/Cas9 lipid nanoparticles achieves robust and persistent in vivo genome editing","volume":"22","author":"Finn","year":"2018","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0510","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","article-title":"Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing","volume":"11","author":"Wei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0515","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jconrel.2020.12.013","article-title":"Lipid nanoparticles loaded with ribonucleoprotein-oligonucleotide complexes synthesized using a microfluidic device exhibit robust genome editing and hepatitis B virus inhibition","volume":"330","author":"Suzuki","year":"2021","journal-title":"J. Control. Release Off. J. Control. Release Soc."},{"issue":"4","key":"10.1016\/j.jconrel.2022.01.013_bb0520","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"21","key":"10.1016\/j.jconrel.2022.01.013_bb0525","doi-asserted-by":"crossref","first-page":"eabg3217","DOI":"10.1126\/sciadv.abg3217","article-title":"Scaffold-mediated CRISPR-Cas9 delivery system for acute myeloid leukemia therapy","volume":"7","author":"Ho","year":"2021","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0530","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0535","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1038\/s41467-021-26714-w","article-title":"Low immunogenicity of LNP allows repeated administrations of CRISPR-Cas9 mRNA into skeletal muscle in mice","volume":"12","author":"Kenjo","year":"2021","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.jconrel.2022.01.013_bb0540","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"6481","key":"10.1016\/j.jconrel.2022.01.013_bb0545","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0550","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1817426","article-title":"CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia","author":"Xu","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0555","doi-asserted-by":"crossref","first-page":"20611","DOI":"10.1038\/srep20611","article-title":"CRISPR\/Cas9-mediated gene knockout in the mouse brain using in utero electroporation","volume":"6","author":"Shinmyo","year":"2016","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0560","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1080\/10717544.2018.1474964","article-title":"Delivering CRISPR: a review of the challenges and approaches","volume":"25","author":"Lino","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0565","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.omtm.2021.04.002","article-title":"Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I","volume":"21","author":"Gu","year":"2021","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0570","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.omtm.2020.03.002","article-title":"Germline CRISPR\/Cas9-mediated gene editing prevents vision loss in a novel mouse model of Aniridia","volume":"17","author":"Mirjalili Mohanna","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Dev"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0575","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.addr.2013.11.008","article-title":"Understanding ultrasound induced sonoporation: definitions and underlying mechanisms","volume":"72","author":"Lentacker","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119736","article-title":"Ultrasound-activated particles as CRISPR\/Cas9 delivery system for androgenic alopecia therapy","volume":"232","author":"Ryu","year":"2020","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0585","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1177\/0300060519840890","article-title":"Ultrasound microbubble-mediated CRISPR\/Cas9 knockout of C-erbB-2 in HEC-1A cells","volume":"47","author":"Cai","year":"2019","journal-title":"J. Int. Med. Res."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0590","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3109\/03014460.2013.807878","article-title":"An estimation of the number of cells in the human body","volume":"40","author":"Bianconi","year":"2013","journal-title":"Ann. Hum. Biol."},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0595","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0600","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","article-title":"High prevalence of streptococcus pyogenes Cas9-reactive T cells within the adult human population","volume":"25","author":"Wagner","year":"2019","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2022.01.013_bb0605","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nmeth.3993","article-title":"A multi-functional AAV-CRISPR-Cas9 and its host response","volume":"13","author":"Chew","year":"2016","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0610","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41467-019-09693-x","article-title":"Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes","volume":"10","author":"Ferdosi","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0615","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1021\/acs.accounts.9b00106","article-title":"Delivery aspects of CRISPR\/Cas for in vivo genome editing","volume":"52","author":"Wilbie","year":"2019","journal-title":"Acc. Chem. Res."},{"issue":"7493","key":"10.1016\/j.jconrel.2022.01.013_bb0620","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/507423a","article-title":"Preclinical research: make mouse studies work","volume":"507","author":"Perrin","year":"2014","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.jconrel.2022.01.013_bb0625","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41576-020-0217-0","article-title":"A primate view of gene expression","volume":"21","author":"Koch","year":"2020","journal-title":"Nat. Rev. Genet."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0630","doi-asserted-by":"crossref","DOI":"10.1038\/cr.2007.111","article-title":"Regulation of DNA double-strand break repair pathway choice","volume":"18","author":"Shrivastav","year":"2008","journal-title":"Cell Res."},{"issue":"12","key":"10.1016\/j.jconrel.2022.01.013_bb0635","doi-asserted-by":"crossref","DOI":"10.1002\/pro.2552","article-title":"Single nucleotide variations: Biological impact and theoretical interpretation","volume":"23","author":"Katsonis","year":"2014","journal-title":"Protein Sci. Publ. Protein Soc"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0640","series-title":"International Review of Cell and Molecular Biology","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/B978-0-12-394310-1.00004-7","article-title":"Chapter four - new insights into cell cycle regulation and dna damage response in embryonic stem cells","volume":"vol. 299","author":"Suvorova","year":"2012"},{"issue":"18","key":"10.1016\/j.jconrel.2022.01.013_bb0645","article-title":"DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells","volume":"7","author":"Mao","year":"2008","journal-title":"Cell Cycle Georget. Tex"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0650","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-genet-051710-150955","article-title":"Regulation of homologous recombination in eukaryotes","volume":"44","author":"Heyer","year":"2010","journal-title":"Annu. Rev. Genet."},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0655","doi-asserted-by":"crossref","DOI":"10.1038\/nbt.3190","article-title":"Inhibition of non-homologous end joining increases the efficiency of CRISPR\/Cas9-mediated precise [TM: inserted] genome editing","volume":"33","author":"Maruyama","year":"2015","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0660","doi-asserted-by":"crossref","first-page":"21264","DOI":"10.1038\/srep21264","article-title":"Enrichment of G2\/M cell cycle phase in human pluripotent stem cells enhances HDR-mediated gene repair with customizable endonucleases","volume":"6","author":"Yang","year":"2016","journal-title":"Sci. Rep."},{"issue":"30","key":"10.1016\/j.jconrel.2022.01.013_bb0665","article-title":"All-in-one dendrimer-based lipid nanoparticles enable precise HDR-mediated gene editing in vivo","volume":"33","author":"Farbiak","year":"2021","journal-title":"Adv. Mater. Deerfield Beach Fla"},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0670","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/s41467-018-03475-7","article-title":"CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair","volume":"9","author":"Charpentier","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.jconrel.2022.01.013_bb0675","doi-asserted-by":"crossref","DOI":"10.1038\/nprot.2011.301","article-title":"AAV-mediated gene targeting methods for human cells","volume":"6","author":"Khan","year":"2011","journal-title":"Nat. Protoc."},{"issue":"9","key":"10.1016\/j.jconrel.2022.01.013_bb0680","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nmeth.1653","article-title":"High-frequency genome editing using ssDNA oligonucleotides with zinc-finger nucleases","volume":"8","author":"Chen","year":"2011","journal-title":"Nat. Methods"},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2017.09.021","article-title":"Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity","volume":"26","author":"Paulk","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0690","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"1\u201318","author":"Suzuki","year":"2016","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0695","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nrg.2016.28","article-title":"Defining and improving the genome-wide specificities of CRISPR\u2013Cas9 nucleases","volume":"17","author":"Tsai","year":"2016","journal-title":"Nat. Rev. Genet."},{"issue":"7603","key":"10.1016\/j.jconrel.2022.01.013_bb0700","doi-asserted-by":"crossref","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"issue":"7681","key":"10.1016\/j.jconrel.2022.01.013_bb0705","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of a\u2022T to G\u2022C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0710","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.65552","article-title":"Precise base editing for the in vivo study of developmental signaling and human pathologies in zebrafish","volume":"10","author":"Rosello","year":"2021","journal-title":"eLife"},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0715","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1038\/s41467-021-23996-y","article-title":"Efficient precise in vivo base editing in adult dystrophic mice","volume":"12","author":"Xu","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0720","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41551-020-00671-z","article-title":"In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA","volume":"5","author":"Villiger","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0725","first-page":"1","article-title":"Adenine base editor engineering reduces editing of bystander cytosines","author":"Jeong","year":"2021","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0730","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41467-018-08034-8","article-title":"Engineering of high-precision base editors for site-specific single nucleotide replacement","volume":"10","author":"Tan","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0735","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1038\/s41467-020-19690-0","article-title":"A Cas-embedding strategy for minimizing off-target effects of DNA base editors","volume":"11","author":"Liu","year":"2020","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0740","doi-asserted-by":"crossref","DOI":"10.1038\/s41592-020-0832-x","article-title":"A rationally engineered cytosine base editor retains high on-target activity while reducing both DNA and RNA off-target effects","volume":"17","author":"Zuo","year":"2020","journal-title":"Nat. Methods"},{"issue":"4","key":"10.1016\/j.jconrel.2022.01.013_bb0745","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41587-019-0050-1","article-title":"Genome-wide target specificity of CRISPR RNA-guided adenine base editors","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0750","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/s41596-020-00453-6","article-title":"Identifying genome-wide off-target sites of CRISPR RNA\u2013guided nucleases and deaminases with Digenome-seq","volume":"16","author":"Kim","year":"2021","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0755","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41467-018-07988-z","article-title":"Genome-wide profiling of adenine base editor specificity by EndoV-seq","volume":"10","author":"Liang","year":"2019","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0760","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41592-021-01172-w","article-title":"Detect-seq reveals out-of-protospacer editing and target-strand editing by cytosine base editors","volume":"18","author":"Lei","year":"2021","journal-title":"Nat. Methods"},{"issue":"6437","key":"10.1016\/j.jconrel.2022.01.013_bb0765","doi-asserted-by":"crossref","DOI":"10.1126\/science.aav9973","article-title":"Cytosine base editor generates substantial off-target single-nucleotide variants in mouse embryos","volume":"364","author":"Zuo","year":"2019","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0770","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41467-020-15887-5","article-title":"Cytosine base editors with minimized unguided DNA and RNA off-target events and high on-target activity","volume":"11","author":"Yu","year":"2020","journal-title":"Nat. Commun."},{"issue":"6437","key":"10.1016\/j.jconrel.2022.01.013_bb0775","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaw7166","article-title":"Cytosine, but not adenine, base editors induce genome-wide off-target mutations in rice","volume":"364","author":"Jin","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0780","doi-asserted-by":"crossref","DOI":"10.1038\/s41587-021-00933-4","article-title":"In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels","author":"Rothgangl","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0785","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03534-y","article-title":"In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates","volume":"593","author":"Musunuru","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0790","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-019-1711-4","article-title":"Search-and-replace genome editing without double-strand breaks or donor DNA","volume":"576","author":"Anzalone","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0795","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-021-02304-3","article-title":"Prime editing in mice reveals the essentiality of a single base in driving tissue-specific gene expression","volume":"22","author":"Gao","year":"2021","journal-title":"Genome Biol."},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0800","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2021.02.022","article-title":"Engineered prime editors with PAM flexibility","volume":"29","author":"Kweon","year":"2021","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0805","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41587-020-0677-y","article-title":"Predicting the efficiency of prime editing guide RNAs in human cells","volume":"39","author":"Kim","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0810","first-page":"1","article-title":"Application of prime editing to the correction of mutations and phenotypes in adult mice with liver and eye diseases","author":"Jang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0815","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1038\/s41467-020-19136-7","article-title":"Prime editing for functional repair in patient-derived disease models","volume":"11","author":"Schene","year":"2020","journal-title":"Nat. Commun."},{"issue":"7\u20138","key":"10.1016\/j.jconrel.2022.01.013_bb0820","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/s41434-021-00263-9","article-title":"Prime editing - an update on the field","volume":"28","author":"Scholefield","year":"2021","journal-title":"Gene Ther."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0825","article-title":"Dual-AAV delivering split prime editor system for in vivo genome editing","author":"Zhi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.01.013_bb0830","series-title":"Prime Editing Enables Precise Genome Editing in Mouse Liver and Retina","author":"Jang","year":"2021"},{"issue":"7773","key":"10.1016\/j.jconrel.2022.01.013_bb0835","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/s41586-019-1534-3","article-title":"The histone mark H3K36me2 recruits DNMT3A and shapes the intergenic DNA methylation landscape","volume":"573","author":"Weinberg","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0840","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nmeth.3325","article-title":"Functional annotation of native enhancers with a Cas9\u2013histone demethylase fusion","volume":"12","author":"Kearns","year":"2015","journal-title":"Nat. Methods"},{"issue":"3","key":"10.1016\/j.jconrel.2022.01.013_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2014.09.029","article-title":"Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation","volume":"159","author":"Gilbert","year":"2014","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0850","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2013.06.044","article-title":"CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes","volume":"154","author":"Gilbert","year":"2013","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jconrel.2022.01.013_bb0855","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/nmeth.3312","article-title":"Highly efficient Cas9-mediated transcriptional programming","volume":"12","author":"Chavez","year":"2015","journal-title":"Nat. Methods"},{"issue":"9","key":"10.1016\/j.jconrel.2022.01.013_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.03.025","article-title":"Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing","volume":"184","author":"Nu\u00f1ez","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0865","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12013-y","article-title":"In vivo epigenetic editing of Sema6a promoter reverses transcallosal dysconnectivity caused by C11orf46\/Arl14ep risk gene","volume":"10","author":"Peter","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.jconrel.2022.01.013_bb0870","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymthe.2019.08.018","article-title":"dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice","volume":"28","author":"Colasante","year":"2020","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.jconrel.2022.01.013_bb0875","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41592-021-01207-2","article-title":"Transgenic mice for in vivo epigenome editing with CRISPR-based systems","volume":"18","author":"Gemberling","year":"2021","journal-title":"Nat. Methods"},{"issue":"2","key":"10.1016\/j.jconrel.2022.01.013_bb0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2006.02.041","article-title":"A bivalent chromatin structure marks key developmental genes in embryonic stem cells","volume":"125","author":"Bernstein","year":"2006","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jconrel.2022.01.013_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2010.03.018","article-title":"Distinct epigenomic landscapes of pluripotent and lineage-committed human cells","volume":"6","author":"Hawkins","year":"2010","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.jconrel.2022.01.013_bb0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.tig.2014.04.004","article-title":"Mechanisms of epigenetic memory","volume":"30","author":"D\u2019Urso","year":"2014","journal-title":"Trends Genet. TIG"},{"key":"10.1016\/j.jconrel.2022.01.013_bb0895","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semcdb.2019.06.005","article-title":"Molecular mechanisms of epigenetic inheritance: possible evolutionary implications","volume":"97","author":"Sarkies","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"issue":"7","key":"10.1016\/j.jconrel.2022.01.013_bb0900","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.10.025","article-title":"In vivo target gene activation via crispr\/cas9-mediated trans-epigenetic modulation","volume":"171","author":"Liao","year":"2017","journal-title":"Cell"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592200027X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016836592200027X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:40:47Z","timestamp":1777509647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016836592200027X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":180,"alternative-id":["S016836592200027X"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.01.013","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of CRISPR-Cas tools for in vivo genome editing therapy: Trends and challenges","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}